Study details
Enrolling now
Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease
Bernard (Barry) Baumel
NCT IDNCT06781333ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
8
Study length
about 1.1 years
Ages
55–90
Locations
1 site in FL
What this study is about
Researchers are testing if adding one infusion of mesenchymal stem cells to the current treatment with antipsychotic medication may help control behavioral problems in people with a diagnosis of moderate to severe Alzheimer's disease. The trial will last for 412 days and involve approximately 8 adults.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive hMSC
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Neurology